CERC 611

Drug Profile

CERC 611

Alternative Names: (-)-25 LY3130481; LY-3130481

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Cerecor
  • Class Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy

Most Recent Events

  • 27 Sep 2016 Cerecor plans to file an IND application with the US FDA in for Epilepsy
  • 27 Sep 2016 Cerecor plans a phase I trial for Epilepsy in USA
  • 26 Sep 2016 Preclinical trials in Epilepsy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top